Select peptides act on the pathways behind arousal, sexual response, and reproductive-hormone signaling.
5 peptides commonly researched for this goal. Tap any card for the full guide.
An FDA-approved libido peptide (as Vyleesi) with real prescribing data. Also popular off-label for a broader range of sexual health goals.
Read the guideThe unapproved 'tanning peptide' that PT-141 was spun off from. It carries a real mole and skin-monitoring caveat worth surfacing.
Read the guideA peptide sitting at the very top of the reproductive hormone cascade. Genuinely interesting research target, but not a well-mapped self-use protocol.
Read the guideA hormone everyone already makes. FDA-approved for labor, and separately studied off-label (intranasally) for bonding and libido.
Read the guideAn FDA-approved GnRH used heavily off-label alongside TRT to keep natural testicular function running.
Read the guideLibido isn't one switch. It runs on brain signaling, hormone rhythms, and blood flow all at once, which is why the peptides studied here work through very different doors. Most fall into a few groups. The clearest is the melanocortin pathway. PT-141 (bremelanotide) and its parent compound Melanotan II both hit melanocortin receptors in the brain, acting on desire centrally rather than on circulation the way a PDE5 drug does. PT-141 is the standout: it's FDA-approved as Vyleesi for one narrow use, hypoactive sexual desire disorder in premenopausal women, so it carries real prescribing data. Melanotan II is the unapproved 'tanning peptide' PT-141 was spun off from, and it comes with a mole and skin-monitoring caveat.
Two other mechanisms show up. Kisspeptin-10 sits at the very top of the reproductive hormone cascade, upstream of the signals that drive testosterone and estrogen. It's a genuinely interesting research target for arousal and reproductive signaling, but not a well-mapped self-use protocol. Oxytocin, a hormone your body already makes, is studied off-label (usually intranasal) for bonding and libido, and it's FDA-approved for a completely separate use in labor. Gonadorelin, a GnRH analog, is FDA-approved and used heavily off-label alongside testosterone therapy to keep natural testicular function running. Read that lineup and one thing stands out: one of these has direct approval for libido, and the rest are earlier, more experimental, or approved for something else entirely.
| Peptide | Category | Studied for | Evidence |
|---|---|---|---|
| PT-141 (Bremelanotide)Vyleesi | Sexual Health | Libido & Sexual Health | Extensive research |
| Melanotan IIMelanocortin agonist | Sexual Health | Libido & Sexual Health, Skin & Hair | Moderate research |
| Kisspeptin-10Reproductive hormone modulator | Sexual Health | Libido & Sexual Health | Moderate research |
| OxytocinNeurohormone | Sexual Health | Libido & Sexual Health, Cognitive Function | Extensive research |
| GonadorelinGnRH analog | Sexual Health | Libido & Sexual Health | Extensive research |
PT-141 acts on melanocortin receptors in the central nervous system, so its target is desire itself rather than the plumbing. That's the mechanistic difference from erectile-focused drugs, and it's why PT-141 is studied in both men and women. It reached FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which is a specific, tightly defined use, not a general libido booster. Off-label, it's popular for a broader range of sexual health goals, but 'popular off-label' and 'proven for your situation' are not the same thing. It shares its family tree with Melanotan II, the earlier, unapproved compound, so the melanocortin side-effect questions (nausea, flushing, blood-pressure changes, and for Melanotan II the skin and mole monitoring) are worth taking seriously. None of this is medical advice, and none of it is a protocol.
The honest summary: the evidence is uneven. PT-141 has the deepest data because it went through approval. Gonadorelin and Oxytocin are well-characterized molecules, but their libido uses are mostly off-label or adjunctive, not the reason they were approved. Kisspeptin-10 and Melanotan II sit further back, with real research interest but thinner human guidance for this purpose. Low libido also has a long list of non-peptide drivers: sleep, stress, relationship dynamics, medications, thyroid, and hormone levels among them, and a peptide doesn't address any of those. Sourcing and purity are real concerns in a market full of research-only material. If sexual function or desire is bothering you, a clinician who can order labs and rule out underlying causes is the right starting point, not a vial. Use this page to understand the mechanisms, then take questions to someone who can examine you.
There's no single best. PT-141 (bremelanotide) has the strongest evidence because it's the only one here with FDA approval for a libido-related use, as Vyleesi for premenopausal women. But the right fit depends on the person, the cause, and a clinician's assessment. Gonadorelin, Oxytocin, Kisspeptin-10, and Melanotan II work through different mechanisms with less direct proof.
In its approved use, Vyleesi for hypoactive sexual desire disorder in premenopausal women, PT-141 showed enough benefit to clear FDA review, so it does have real prescribing data behind it. It acts centrally on desire through melanocortin receptors. Results vary by person, and much of its wider use is off-label without the same level of evidence. This isn't medical advice.
Safety varies a lot by compound. PT-141 has a documented side-effect profile from trials, including nausea and blood-pressure changes. Melanotan II carries a specific mole and skin-monitoring caveat and isn't approved. Others have thinner human safety data for this purpose. Purity and sourcing add risk. A clinician should weigh your history before anything, and nothing here is a recommendation to use these.
PT-141 works in the brain on melanocortin receptors, targeting desire itself. Common ED drugs work on blood flow instead, relaxing vessels to support an erection. That makes them mechanistically separate tools aimed at different parts of the sexual response. PT-141's approval is specifically for low desire in premenopausal women, not as an erection drug. Talk to a clinician about which problem you're actually addressing.
Kisspeptin-10 sits at the top of the reproductive hormone cascade, upstream of the signals that regulate testosterone and estrogen. That upstream position makes it a genuinely interesting research target for arousal and reproductive signaling. It is not, however, a well-mapped self-use protocol, and the human data for boosting libido specifically remains early. Treat it as a research compound, not an established option.
Gonadorelin is a GnRH analog that's FDA-approved and used heavily off-label alongside testosterone replacement therapy. The goal there is keeping natural testicular function running while on TRT, which supports the hormone side of libido indirectly. It isn't a standalone desire drug. Its role is preserving your own signaling, and any use belongs under the supervision of a clinician managing the underlying hormone therapy.
Educational information only. This is not medical advice. Peptide AI is an informational and tracking platform. Everything on this page is for general education. It is not a substitute for professional medical advice and is not a recommendation to use any compound. Many peptides listed here are research compounds the FDA has not approved for human use. Talk to a qualified, licensed healthcare provider before you start, change, or stop any protocol.
Peptide AI joins your doses, labs, and wearables so you can see which compounds actually move your numbers.